Berzosertib
Drug timelines are a Plus or Pro feature.
8 regulatory and trial events tracked for Berzosertib, covering 2023-10-17 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors [Phase 1, Phase 2]